Cover Image
市場調查報告書

非何傑金氏淋巴瘤:開發中產品分析

Non-Hodgkin Lymphoma - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 192737
出版日期 內容資訊 英文 1740 Pages
訂單完成後即時交付
價格
Back to Top
非何傑金氏淋巴瘤:開發中產品分析 Non-Hodgkin Lymphoma - Pipeline Review, H1 2017
出版日期: 2017年05月31日 內容資訊: 英文 1740 Pages
簡介

非何傑金氏淋巴瘤(NHL,或僅稱「淋巴瘤」),是從人體免疫系統淋巴球發病的癌症之一。人體各處均有可能出現,癌細胞擴展速度也完全因人而異。主要的症狀有盜汗、間歇性發熱·發冷、發癢、頭部·腋下·鼠蹊部等淋巴節肥大化、體重減少、咳嗽·呼吸急促(胸腺和胸部淋巴節受侵襲)、氣管和其他呼吸道的壓迫感、腹痛·膨脹感、食慾不振、便秘、噁心·嘔吐·頭痛、欠缺集中力、性格變化、癲癇(腦部受侵襲)等。主要的治療方法有外科手術和放射治療、化療等。

本報告提供全球各國治療非何傑金氏淋巴瘤所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

非何傑金氏淋巴瘤概要

治療藥的開發

非何傑金氏淋巴瘤:治療藥的評估

非何傑金氏淋巴瘤開發治療藥的企業

藥物簡介

非何傑金氏淋巴瘤治療藥:開發暫停的產品

非何傑金氏淋巴瘤治療藥:開發中止的產品

非何傑金氏淋巴瘤相關產品的開發里程碑

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9376IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2017, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.

Non-Hodgkin lymphoma (also known as non-Hodgkin lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body's immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 28, 137, 124, 5, 123, 18 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 15, 17, 16 and 4 molecules, respectively.

Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Non-Hodgkin Lymphoma - Overview
  • Non-Hodgkin Lymphoma - Therapeutics Development
  • Non-Hodgkin Lymphoma - Therapeutics Assessment
  • Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development
  • Non-Hodgkin Lymphoma - Drug Profiles
  • Non-Hodgkin Lymphoma - Dormant Projects
  • Non-Hodgkin Lymphoma - Discontinued Products
  • Non-Hodgkin Lymphoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Non-Hodgkin Lymphoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..15), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..16), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..17), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..18), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..19), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..20), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..21), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..22), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..23), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..24), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..25), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..26), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..27), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..28), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..29), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..30), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..31), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..32), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..33), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..34), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..35), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..36), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..37), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..38), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..39), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..40), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..41), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..42), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..43), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..44), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..45), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..46), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..47), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by ACEA Biosciences Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Affitech A/S, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Aileron Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Alfa Wassermann SpA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corp, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Amgen Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Aptose Biosciences Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Arno Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by ArQule Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Arven Ilac, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Arvinas Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Asana BioSciences LLC, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Atara Biotherapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by BeiGene Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by BioAtla LLC, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Biocon Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by BioLineRx Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Bionovis SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by BioNTech AG, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Biothera Pharmaceutical Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Calimmune Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Cascadian Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Celgene Corp, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Cell Medica Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Cell Source Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Cell>Point LLC, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Cellectar Biosciences Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Cellectis SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Celleron Therapeutics Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Celltrion Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Celon Pharma SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Centrose LLC, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by CerRx Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Cleave Biosciences Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Clevexel Pharma SAS, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by CSPC Pharmaceutical Group Limited, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Curis Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by CytomX Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Debiopharm International SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Denovo Biopharma LLC, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corp, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by eFFECTOR Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Eisai Co Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by EpiZyme Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Erytech Pharma SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Evotec AG, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Forma Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Formula Pharmaceuticals Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Forty Seven Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Galderma SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Genentech Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Genor BioPharma Co Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Genosco Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by H3 Biomedicine Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Heidelberg Pharma GmbH, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Humorigin Biotechnology Corp, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Hutchison China MediTech Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by iDD biotech SAS, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by IGF Oncology LLC, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Ignyta Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by ImmunGene Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by ImmunoGen Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Immunomedics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Immunovaccine Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Immunwork Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Incyte Corp, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Inflection Biosciences Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Innate Pharma SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Japan Tobacco Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by JHL Biotech Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by K-Stemcell Co Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Kite Pharma Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Klyss Biotech Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Komipharm International Co Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by LFB SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by MacroGenics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by MedImmune LLC, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Medivir AB, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by MEI Pharma Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by MENTRIK Biotech LLC, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Merck & Co Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Mesoblast Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by miRagen Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Moleculin Biotech Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Molplex Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by NantKwest Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by NBE-Therapeutics AG, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Oncobiologics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Oncopeptides AB, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by OncoSec Medical Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Oncovir Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Oncternal Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Onxeo SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Oxford BioTherapeutics Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by OXIS International Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Patrys Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Pharma Mar SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Philogen SpA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by PIQUR Therapeutics AG, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Respiratorius AB, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Sandoz International GmbH, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Sareum Holdings Plc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Selvita SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Senhwa Biosciences Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Sierra Oncology Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau SpA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Simcere Pharmaceutical Group, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Solasia Pharma KK, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Soligenix Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Sunesis Pharmaceuticals Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Surface Oncology Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Sutro Biopharma Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Targazyme Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Ltd, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Transgene SA, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Trillium Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by United BioPharma Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Verastem Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Vivolux AB, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Xencor Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by ZIOPHARM Oncology Inc, H1 2017
  • Non-Hodgkin Lymphoma - Pipeline by Zymeworks Inc, H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..9), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..10), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..11), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..12), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..13), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..14), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..15), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..16), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..17), H1 2017
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..18), H1 2017
  • Non-Hodgkin Lymphoma - Discontinued Products, H1 2017
  • Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..1), H1 2017
  • Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..2), H1 2017
  • Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..3), H1 2017
  • Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..4), H1 2017
  • Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..5), H1 2017
  • Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..6), H1 2017
  • Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..7), H1 2017

List of Figures

  • Number of Products under Development for Non-Hodgkin Lymphoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top